Please use this identifier to cite or link to this item:
Lack of Antiviral Activity of Darunavir against SARS-CoV-2
Sandra De Meyer.
Denisa Bojkova.
Jindrich Cinati.
Ellen Van Damme.
Christophe Buyck.
Marnix Van Loock.
Brian Woodfall.
Sandra Ciesek.
Acceso Abierto
Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC50 >100 M). Remdesivir, used as a positive control, showed potent antiviral activity (EC50 = 0.38 M). Overall, the data do not support the use of DRV for treatment of COVID-19.
Appears in Collections:Artículos científicos

Upload archives

File SizeFormat 
1101277.pdf123.76 kBAdobe PDFView/Open